A thirty-eight-year-old project director at a fintech in Yaba weighs sixty-one kilograms, runs the Lekki–Ikoyi bridge most Saturdays at a respectable pace, and has not had a sick day in three years that she can place. Her last full blood panel was at her undergraduate intake medical at Covenant in 2008. The fatigue that brings her into the practice this Tuesday is the kind she has been writing off as travel, as work, as Lagos — three flights a fortnight to Abuja, the usual three a.m. release windows, the protein-bar lunches eaten over Jira tickets. The HbA1c returns 8.7. The fasting glucose is 11.4. The triglycerides are 286. Her first sentence in the consulting room, before any of the explanation has landed, is the sentence almost every healthy-looking Nigerian patient says in this chair.
But I don't look sick.
She is correct. She does not look sick. She is also, by the most generous threshold the international guidelines permit, frankly diabetic, and has been so for at least eighteen months on the slope of her trajectory. The two facts are not in conflict. They are the diagnosis.
This is the most consequential clinical pattern in private practice in Lagos and Abuja in the patient cohort the practice sees most often: the slim, active, well-presented, professionally successful Nigerian under fifty whose appearance has been treated by themselves, and frequently by their primary physician, as evidence of metabolic health. It is not evidence of anything. The body is the last organ to advertise its dysfunction, and in the Nigerian phenotype it advertises later than in almost any population in which the screening cadences of Western medicine were originally calibrated.
The compensation curve
The reason looking healthy is not a diagnosis is mechanical, and the mechanics are the same in a forty-year-old in Yaba as in a forty-year-old in Stockholm or Boston. The body is built to compensate. The pancreas of a person sliding into Type 2 diabetes does not fail in one quarter. It overproduces insulin for years — sometimes a decade — to keep the fasting glucose in a range the patient and the routine annual physical will accept as normal. The blood pressure of a person developing essential hypertension does not climb in a straight line. It climbs in increments small enough that the cardiovascular system, which is also built to compensate, remodels itself silently around the new load. The kidney does not announce a falling glomerular filtration rate. It loses thirty per cent of its function before any single creatinine value crosses any single guideline threshold and reaches the attention of any single doctor.
This is the compensation curve, and it is the central fact every screening physician works against. The compensation curve produces patients who feel well and are unwell. It produces patients whose families, friends, gym instructors, and physicians look at them and certify them as healthy on the visible evidence. It produces patients who, at the moment the compensation finally fails, are not at the beginning of a disease but well into its second act, with structural damage to the organs that have been quietly accommodating the underlying dysfunction for a decade.
The Lagos project director with an HbA1c of 8.7 is not at the start of her diabetes. She is at the end of the compensation phase of her diabetes. Her pancreas has been beta-cell stressed for years. The microvasculature of her retinas has been exposed to glycaemic excursions for years. The first time her body produced a symptom legible enough to bring her into a consulting room — the unspecific fatigue — was the first time the compensation finally faltered, which is to say the latest possible point at which the diagnosis could have been made.
The Nigerian phenotype problem
There is a second layer to this, and it is the layer most poorly served by the screening conversation as it presently runs in Lagos and Abuja primary care. The thresholds at which Type 2 diabetes, dyslipidaemia, and cardiovascular risk become clinically actionable in Western populations are not the thresholds at which the same conditions become clinically dangerous in West African populations. The literature on this is now nearly two decades deep and consistent in direction.
The phenotype that produces the highest rates of metabolic dysfunction in the Nigerian adult is not the overweight phenotype. It is the lean, central-obesity phenotype — sometimes called thin-outside-fat-inside — in which a body mass index that would be classed unremarkable in any Western clinic carries a visceral fat distribution that drives insulin resistance, hepatic steatosis, and atherogenic dyslipidaemia at body weights the patient's mirror and the patient's friends do not flag. The waist-to-hip ratio is the more honest measure here than the BMI, and the waist-to-hip ratio is not measured at the average annual physical in the average Lagos private hospital.
The blood-pressure threshold matters in the same way. The cardiovascular risk associated with sustained systolic readings of 135 to 140 in West African and African-diaspora populations is meaningfully higher, at every age bracket, than the same readings in the population the threshold of 140 was originally calibrated for. The Jackson Heart Study, INTERHEART Africa, and the African-American CARDIA cohorts have been consistent on this for two decades. The Lagos consultant managing an executive with a "borderline" 138/86 and reassuring him that it is "almost normal" is reassuring him against a risk calculation drawn from the wrong population. In the patient in front of him, 138/86 sustained over a decade is not borderline. It is hypertensive disease with end-organ damage that has not yet been documented because no one has gone looking.
The five conditions the Nigerian middle class is missing
In the practice, the five conditions that show up most frequently in the I don't look sick patient are the same five conditions across age, sex, and industry. They are worth naming, because the conversation about screening tends to collapse into a vague gesture toward "checkups" without specifying what the checkup is actually for.
Type 2 diabetes and pre-diabetes. The HbA1c is the single highest-yield test in the screening menu and the most under-ordered. A fasting glucose alone misses the diagnosis in the patient whose pancreas is still compensating well at six in the morning but loses control at every meal. The cohort of patients walking around Lagos and Abuja with an HbA1c between 6.5 and 8.5, no symptoms, and no diagnosis is large and clinically visible to anyone running the test as a routine.
Hypertension. A single in-clinic blood pressure is the lowest-quality information the screening physician can act on. Ambulatory monitoring over a forty-eight-hour window catches the nocturnal non-dipper, the white-coat normotensive who is hypertensive on a Tuesday morning at the office, and the masked hypertensive whose clinic readings are reassuring but whose home readings are not. The cost of the monitor relative to the cost of the stroke is a ratio not seriously debated in the screening literature.
Dyslipidaemia, including Lipoprotein(a). A standard lipid panel is no longer adequate. Lipoprotein(a) is genetically determined, elevated in roughly twenty per cent of the population, conveys a cardiovascular risk independent of LDL, is measured once in a lifetime, and is essentially never ordered in Nigerian primary care. The patient with a "normal" lipid panel and a Lipoprotein(a) of 90 has a cardiovascular trajectory that no statin titration based on the standard panel will catch.
Non-alcoholic fatty liver disease. Now affecting somewhere between fifteen and thirty per cent of the adult population in published Nigerian and West African cohorts, NAFLD is clinically silent until late. The screening tools — a liver ultrasound, an ALT trend, a FIB-4 score derived from routine bloods — are cheap, available, and almost never run. The patient with an ALT trending from 28 to 41 to 58 across three annual physicals is being told each time that the value is "within normal limits" because the threshold for action is set at the upper reference value rather than the trajectory.
Sub-clinical atherosclerosis. A coronary artery calcium score in the patient over forty with any combination of family history, central adiposity, dyslipidaemia, or hypertension is the most prognostically powerful screening test available in cardiovascular medicine. It is widely available in Lagos and Abuja, almost never ordered in routine practice, and is the test that most cleanly distinguishes the asymptomatic patient who needs aggressive intervention now from the asymptomatic patient who genuinely does not.
None of these tests is exotic. None is unavailable. None is expensive at the scale of the income of the patient who needs it. Each catches a disease the patient cannot feel and the mirror cannot see.
What the screening interval is actually for
The deeper reason looking healthy is not a diagnosis is that screening exists precisely for the phase of the disease at which the patient feels well. By the time the patient feels unwell, the screening question is already moot. The conversation the screening physician is trying to have is not the conversation that begins with the patient describing a symptom. It is the conversation that begins with a number on a panel the patient was not expecting and does not yet feel.
The clinical work that produces the best long-run outcomes in the populations the practice has followed for a decade is not the heroic intervention in the established disease. It is the unsentimental rolling collection of numbers, trajectories, and physiological measurements in the patient who has nothing to report, against benchmarks that are tracked over years and acted on at the inflexion point rather than at the failure point. It is the creatinine that has trended from 79 to 96 to 118 over three annual visits, identified at 96 and acted on, rather than identified at 168 with the patient now feeling unwell and the kidneys now structurally compromised. It is the HbA1c that has trended from 5.4 to 5.9 to 6.3, identified at 5.9 and reversed with twelve months of weight, sleep, and exercise rather than identified at 8.7 with a prescription for metformin and the irreversible loss of beta-cell mass already in the rear-view mirror.
This is what the annual physical at scale is supposed to do, and it is what the annual physical in Nigerian primary care most often does not. The reasons are familiar — the standard panel is the panel that gets ordered because it is the panel that gets reimbursed, the trajectory is not constructed because the same patient sees a different doctor each year, the threshold rather than the trend is what gets acted on. None of these are clinical limits. They are operational limits, and they are the part of the problem the patient and the practice can fix together.
The honest close
The patient at the top of this piece is now on metformin, on a structured exercise progression, on a sleep protocol that has moved her average from five hours to seven, and on a six-monthly cadence of HbA1c, lipid panel, blood pressure trace, and liver enzymes that will, over the next eighteen months, tell us whether the beta-cell reserve she has left is enough to put her into the cohort that can come off pharmacological therapy or the cohort that cannot. She is also, by any measure she or her family or her physician would have applied eighteen months ago, exactly as healthy-looking as she was then.
The lesson, if there is one, is older than the practice and older than the literature. Appearance is not a diagnosis. Feeling well is not a diagnosis. A normal-looking weight, a respectable Saturday pace, and an absence of symptoms are not diagnoses. They are, at best, the absence of a particular kind of evidence, in a body that is built to keep that evidence absent until the disease is well established.
The number on the panel is the diagnosis. The trajectory across the panels is the diagnosis. The thirty seconds a clinician spends comparing this year's creatinine to the last two years' is the diagnosis. Everything else is what the patient looks like in the waiting room, which is not the same thing, and which a serious screening practice has stopped confusing for the same thing.
The work of preventive medicine in the Nigerian middle class is not glamorous. It is the steady, unrushed, properly-ordered, properly-trended construction of a clinical picture of a patient who feels fine, in the years before the picture begins to argue back. The reward of the work is not the heroic save. It is the years in which the heroic save did not need to happen, because the inflexion point was caught early, and the patient went on looking healthy because she actually was.